Overcoming the bottleneck: Why the transition from clinical trial to market supply determines success
The path of a pharmaceutical product from development to the patient is a marathon, not a sprint. Yet often, just before the finish line — at the transition from the clinical phase (investigational medicinal products) to commercial market supply — unnecessary friction losses occur. Many pharmaceutical companies work with specialised small suppliers during the clinical…